Su and colleagues have elaborated that R-2-hydroxyglutarate (R-2HG) exhibits broad and variable anti-proliferation effects in leukemia and glioma since it increases global m6A RNA modification in the sensitive cells via suppressing FTO. The gene discussed is FTO; the disease is leukemia.